Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipella Pharmaceuticals Inc LIPO

Healthcare Biotechnology
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical... see more

Recent & Breaking News (NDAQ:LIPO)

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

GlobeNewswire April 3, 2024

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

GlobeNewswire March 5, 2024

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

GlobeNewswire February 20, 2024

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

GlobeNewswire December 20, 2023

FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease

PR Newswire November 10, 2023

Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

PR Newswire October 25, 2023

Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

PR Newswire October 24, 2023

Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference

Accesswire October 23, 2023

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus

PR Newswire October 20, 2023

Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology

PR Newswire September 21, 2023

Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

PR Newswire May 15, 2023

Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting

PR Newswire May 1, 2023

Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite

PR Newswire April 17, 2023

Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent

PR Newswire April 5, 2023

Lipella Provides Business Update and Reports 2022 Financial Results

PR Newswire March 31, 2023

Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological Association

PR Newswire March 16, 2023

Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board

PR Newswire March 1, 2023

Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10

PR Newswire January 11, 2023

Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San Francisco

PR Newswire January 9, 2023